Pasithea therapeutics announces pas-004 abstract accepted for poster presentation at 2024 asco annual meeting

South san francisco, calif. and miami, april 29, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor for the treatment of neurofibromatosis type 1 (nf1) and other indications, today announced the acceptance of an abstract for poster presentation at the american society of cancer oncology (“asco”), which will be held in chicago from may 31 – june 4, 2024.
KTTA Ratings Summary
KTTA Quant Ranking